Matters of Ethics, Trust, and Potential Liability for Autonomous Systems

Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich.This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.The objective of this panel was to discuss issues related to the development and use of autonomous systems, with specific focus on the overriding themes of ethical considerations and potential liability for Human Factors and Ergonomics (HF/E) professionals who are involved in their development. Chris Brill provided opening remarks to frame the discussion and introduce the panelists. James Bliss discussed legal implications related to our collective penchant for developing conservative, false-alarm prone automation. Peter Hancock advocated for human-centered constraints on autonomous systems, as they may, one day, pose an existential threat to humanity. Dietrich Manzey discussed ethical considerations for autonomous systems, including how design can encourage ethical user behavior. Joachim Meyer argued that HF/E professionals have an obligation to help designers understand the ethical implications of poor design, particularly in the context of autonomous systems. Lastly, Alison Vredenburgh provided thoughts on potential liability for HF/E professionals, particularly in light of the relative newness of autonomous systems. The panel then turned to facilitated discussion with panelists and audience members. Specific themes included the boundaries of our responsibilities as HF/E professionals for ill-conceived or morally-objectionable systems, potential implications of manipulating user trust through design, cross-cultural perspectives on public acceptance and legal peril, and how concerns might differ by domain (e.g., medical vs. combat vs. manufacturing). The session concluded with panelists summarizing how ethics influence design and recommendations for how HF/E professionals can potentially protect themselves from legal liability for mishaps involving autonomous systems they helped develop

Embedded EthiCS: Integrating ethics broadly across computer science education

Computing technologies have become pervasive in daily life, sometimes bringing unintended but harmful consequences. Forstudents to learn to think not only about what technology they could create, but also about what technology they shouldcreate, computer science curricula must expand to include ethical reasoning about the societal value and impact of these technologies. This paper presents Embedded EthiCS, a novel approachto integrating ethics into computer science education that incorporates ethical reasoning throughout courses in the standard computer science curriculum. It thus changes existing courses rather than requiring wholly new courses. The paperdescribes a pilot Embedded EthiCS program that embeds philosophers teaching ethical reasoning directly into computer science courses. It discusses lessons learned and challenges to implementing such a program across different types of academic institution

Stem cell fate in cancer growth, progression and therapy resistance

Although we have come a long way in our understanding of the signals that drive cancer growth, and how these signals can be targeted, effective control of this disease remains a key scientific and medical challenge. The therapy resistance and relapse that are commonly seen are driven in large part by the inherent heterogeneity within cancers that allows drugs to effectively eliminate some, but not all, malignant cells. Here, we focus on the fundamental drivers of this heterogeneity by examining emerging evidence that shows that these traits are often controlled by the disruption of normal cell fate and aberrant adoption of stem cell signals. We discuss how undifferentiated cells are preferentially primed for transformation and often serve as the cell of origin for cancers. We also consider evidence showing that activation of stem cell programmes in cancers can lead to progression, therapy resistance and metastatic growth and that targeting these attributes may enable better control over a difficult disease